Liver Functional Evaluation Using Gadoxetic Acid Versus the Gold Standard Hepatobiliary Scintigraphy in Patients with Bile Duct Diseases

Objective. To compare liver function assessments using Gd-EOB-DTPA-enhanced MRI and the gold standard hepatobiliary scintigraphy (HBS) in patients with bile duct diseases.

Material and methods. The investigation enrolled 18 patients (male/female = 11/7; age, 29–70 years, Klatskin tumor (n=16), bile duct epithelial dysplasia (n=1), intrahepatic cholangiolithiasis (n=1)) after biliary decompression, who underwent 21 paired MRIs and 99mTc-mebrofenin HBS at a study interval of no more than 3 days. In the same regions of interest with a size of 30–50 pixels located in liver segments II–III, IV, V–VIII, and VI–VII, a MRI signal was measured before MR contrast agent (MRCA) injection into the standard vascular phases and at 10, 20, 30 and 40 minutes, then the signal was expressed as a percentage of intensity compared to the precontrast series. After MR volumetry, the functional volumes of the left and right liver lobes were also defined as the area under the MRCA accumulation curve, which was multiplied by the lobe volume and expressed as a percentage of the similarly calculated function of the entire liver. Similar intensity parameters and functional volumes were estimated for a HBS study.

Results. The lobe functional volumes measured by the two methods were highly correlated (R=0.8; p<0.001) and did not show a significant difference at all when comparing with the Mann–Whitney test (p>0.3). The excretion rate of 99mTc-mebrofenin was also highly correlated with MRI findings (R=0.5–0.9; p<0.05). Conclusion. Gd-EOB-DTPA-enhanced MRI revealed a high correlation with the gold standard; however, additional studies are needed to clarify the possibilities and limitations of replacing one method with another one.><0.05).

Conclusion. Gd-EOB-DTPA-enhanced MRI revealed a high correlation with the gold standard; however, additional studies are needed to clarify the possibilities and limitations of replacing one method with another one.

1. Chapelle T., Op De Beeck B., Huyghe I., Francque S., Driessen A., Roeyen G. et al. Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure? HPB (Oxford). 2016; 18 (6): 494–503. DOI:10.1016/j.hpb.2015.08.002

2. Olthof P.B., Coelen R.J.S., Bennink R.J., Heger M., Lam M.F., Besselink M.G. et al. (99m)Tc-mebrofenin hepatobiliary scintigraphy predicts liver failure following major liver resection for perihilar cholangiocarcinoma. HPB (Oxford). 2017; 19 (10): 850–8. DOI: 10.1016/j.hpb.2017.05.007

3. Olthof P.B., van Gulik T.M., Bennink R.J. Optimal use of hepatobiliary scintigraphy before liver resection. HPB. 2016; 18 (10): 870. DOI: 10.1016/j.hpb.2016.06.008

4. Stieger B., Heger M., de Graaf W., Paumgartner G., van Gulik T. The emerging role of transport systems in liver function tests. Eur. J. Pharmacol. 2012; 675 (1–3): 1–5. DOI:10.1016/j.ejphar.2011.11.048

5. Geisel D., Ludemann L., Froling V., Malinowski M., Stockmann M., Baron A. et al. Imaging-based evaluation of liver function: comparison of (99m)Tc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur. Radiol. 2015; 25 (5): 1384–91. DOI: 10.1007/s00330-014-3536-8

6. Rassam F., Zhang T., Cieslak K.P., Lavini C., Stoker J., Bennink R.J. et al. Comparison between dynamic gadoxetateenhanced MRI and 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT for quantitative assessment of liver function. Eur. Radiol. 2019; 29 (9): 5063–72. DOI:10.1007/s00330-019-06029-7

7. Thian Y.L., Riddell A.M., Koh D.-M. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imag. Offic. Publ. Intern. Cancer Imag. Soc. 2013; 13 (4): 567–79. DOI: 10.1102/1470-7330.2013.0050

8. Subramanian R.M., Chandel N., Budinger G.R., Schumacker P.T. Hypoxic conformance of metabolism in primary rat hepatocytes: a model of hepatic hibernation. Hepatology. 2007; 45 (2): 455–64.

9. Kan V.K. Diagnostics and treatment of the patients with cholestasis. Russian Medical Journal. 1998; 7: 8 (in Russ.).

10. Lee J.J., Schindera S.T., Jang H.J., Fung S., Kim T.K. Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis. Abdom. Radiol. (NY). 2017; 42 (12): 2898–908. DOI: 10.1007/s00261-017-1328-8

11. Nilsson H., Blomqvist L., Douglas L., Nordell A., Jacobsson H., Hagen K. et al. Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J. Magn. Reson. Imag. 2014; 39 (4): 879–86. DOI: 10.1002/ jmri.24250

12. Ringe K.I., Hinrichs J., Merkle E.M., Weismüller T.J., Wacker F., Meyer B.C. Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion. J. Magn. Res. Imag. 2014; 40 (1): 106–12. DOI:10.1002/jmri.24381

13. Lee J.M., Zech C.J., Bolondi L., Jonas E., Kim M.J., Matsui O. et al. Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J. Radiol. 2011;12 (4): 403–15. DOI: 10.3348/kjr.2011.12.4.403